Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shozo Nishida

Showing results (51-60 of 126) with videos related to

Pageof 13
Sort By:
Biochemical Pharmacology|October 23, 2012
Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathwayMasanobu Tsubaki, Tatsuki Itoh, Takao Satou, et al.
American Journal of Cancer Research|August 11, 2018
Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1/2 activationMasanobu Tsubaki, Tomoya Takeda, Mikihiro Matsumoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 17, 2020
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer]Keiji Mashimo, Daichiro Fujiwara, Tadafumi Hoshida, et al.
Life Sciences|December 5, 2003
Pretreatment with PKC inhibitor triggers TNF-alpha induced apoptosis in TNF-alpha-resistant B16 melanoma BL6 cellsShozo Nishida, Shohei Yoshioka, Saori Kinoshita-Kimoto, et al.
Oncology Letters|October 25, 2021
Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survivalTomoya Takeda, Masanobu Tsubaki, Natsuki Kato, et al.
Oncology Reports|October 1, 2020
AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora BTomoya Takeda, Masanobu Tsubaki, Shuji Genno, et al.
Clinical and Experimental Medicine|October 7, 2018
RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cellsKeiji Mashimo, Masanobu Tsubaki, Tomoya Takeda, et al.
Biomedicines|January 7, 2021
Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer CellsMasanobu Tsubaki, Shuuji Genno, Tomoya Takeda, et al.
Molecular and Cellular Endocrinology|May 15, 2012
Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2Masanobu Tsubaki, Takao Satou, Tatsuki Itoh, et al.
Cytokine|May 30, 2021
Interleukin 19 suppresses RANKL-induced osteoclastogenesis via the inhibition of NF-κB and p38MAPK activation and c-Fos expression in RAW264.7 cellsMasanobu Tsubaki, Tomoya Takeda, Takuya Matsuda, et al.
Pageof 13

Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
Biochemical Pharmacology|October 23, 2012
Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathwayMasanobu Tsubaki, Tatsuki Itoh, Takao Satou, et al.
American Journal of Cancer Research|August 11, 2018
Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1/2 activationMasanobu Tsubaki, Tomoya Takeda, Mikihiro Matsumoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 17, 2020
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer]Keiji Mashimo, Daichiro Fujiwara, Tadafumi Hoshida, et al.
Life Sciences|December 5, 2003
Pretreatment with PKC inhibitor triggers TNF-alpha induced apoptosis in TNF-alpha-resistant B16 melanoma BL6 cellsShozo Nishida, Shohei Yoshioka, Saori Kinoshita-Kimoto, et al.
Oncology Letters|October 25, 2021
Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survivalTomoya Takeda, Masanobu Tsubaki, Natsuki Kato, et al.
Oncology Reports|October 1, 2020
AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora BTomoya Takeda, Masanobu Tsubaki, Shuji Genno, et al.
Clinical and Experimental Medicine|October 7, 2018
RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cellsKeiji Mashimo, Masanobu Tsubaki, Tomoya Takeda, et al.
Biomedicines|January 7, 2021
Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer CellsMasanobu Tsubaki, Shuuji Genno, Tomoya Takeda, et al.
Molecular and Cellular Endocrinology|May 15, 2012
Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2Masanobu Tsubaki, Takao Satou, Tatsuki Itoh, et al.
Cytokine|May 30, 2021
Interleukin 19 suppresses RANKL-induced osteoclastogenesis via the inhibition of NF-κB and p38MAPK activation and c-Fos expression in RAW264.7 cellsMasanobu Tsubaki, Tomoya Takeda, Takuya Matsuda, et al.
Pageof 13